Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Bulk RNA-seq analysis of PDAC tumor Cells

ABSTRACT: Bulk RNA-seq analysis of PDAC tumor Cells

PROVIDER: PRJNA807153 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18038213_1.fastq.gz	Fastqsanger.gz
	SRR18038213_2.fastq.gz	Fastqsanger.gz
	SRR18038214_1.fastq.gz	Fastqsanger.gz
	SRR18038214_2.fastq.gz	Fastqsanger.gz
	SRR18038215_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Bulk RNA-seq analysis of PDAC tumor Cells

Project description:Orthotopic PDAC tumor were established with KPC and KPSC cells, respectively. After about 10-14 days, PDAC cells with Setd2-KO and Setd2-WT were sorted from orthotopic PDAC tumor by DPAI-CD45.2-Pdpn-Epcam+, and used for RNA preparation.

2024-08-07 | GSE196752 | GEO

RNA-seq of PDAC tissues grown as patient-derived tumor xenografts

Project description:Pancreatic adenocarcinoma (PDAC) is one of the most lethal human malignancies and a major health problem. Patient-derived tumor xenografts (PDTXs) have been increasingly used as a prime approach for preclinical studies despite being insufficiently characterized as a model of the human disease and its diversity. Extensive multiomics characterization of these PDTXs have demonstrated their utility as a suitable model for preclinical studies, representing the diversity of the primary cancers. We performed a multi-factorial integrative analysis of genome-wide ChIP-seq on multiple histone modifications, as well as RNA-seq on subcutaneous PDTXs from 24 PDAC samples obtained either surgically or using diagnostic biopsies (endoscopic ultrasound guided fine needle aspirate). In the dataset, ChIP-seq for five distinct histone marks (H3K4me1, H3K27ac, H3K4me3, H3K27me3, and H3K9me3) and RNA-seq was carried out to generate new knowledge on the epigenetic landscapes underlying the heterogeneity of PDAC tissues grown in this manner. <br>Note: Sample phenotypes have been updated on 2020-09-11 to correct the swapped labels between \"classical\" and \"basal\" phenotypes.

2018-05-29 | E-MTAB-5639 | biostudies-arrayexpress

Bulk RNA-Seq gene expression data for 289 primary and metastatic pancreatic ductal adenocarcinoma (PDAC) tumor samples from FFPE blocks.

Project description:Pancreatic Ductal Adenocarcinoma (PDAC) is a deadly disease with a 5 year overall survival rate of 11%. In order to better understand and characterized PDAC we have performed RNAseq on 289 primary and metastatic PDAC tumors collected at our center. Nucleic acids (RNA and DNA) were extracted from formalin fixed paraffin embeded FFPE tumor tissue with tumor enriched regions identified by pathologic analysis. RNA sequencing and resulting gene expression data was then used to study biologic differences in primary PDAC tumors that metastasized to either the liver or to the lung but not liver based on clinical data review. A novel gene expression signature was identified for liver vs lung avid metastatic properties. Samples in the entire cohort were then scored based on this gene signature. Pathway analysis revealed that samples high for this signature (as well as liver cohort patient samples) were enriched for pathways involved in ongoing replication stress response, and this was associated with poorer patient outcome.

2024-09-30 | GSE205154 | GEO

Bulk RNA-Seq of human neutrophils and monocytes isolated from healthy controls, G-CSF-treated donors, HSCT, PDAC and IPMN patients

Project description:We aimed to characterize transcriptome plasticity of human myeloid cells in response to stress induced myelopoiesis. We performed bulk RNA sequencing (RNA-Seq) analyses of normal density neutrophils (NDNs), low density neutrophils (LDNs), and monocytes isolated from the peripheral blood (PB) of healthy controls (n=19), of G-CSF-treated donors (n=17) as well as of patients receiving hematopoietic stem cell transplantation (HSC-T; n=8), patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC; n=15) or intraductal papillary mucinous neoplasms (IPMN; n=14). We also analyzed neutrophil differentiation intermediates from bone marrow samples of controls (n=3) or HSC-T patients (n=7). We generated a total of 210 RNA-Seq samples from 73 individuals.

2022-11-29 | E-MTAB-11190 | biostudies-arrayexpress

RNA-seq analyses of PDAC cells

Project description:RNA-seq analyses of PDAC cells

| PRJNA722471 | ENA

ChIP-seq of PDAC tissues grown as patient-derived tumor xenografts

2018-05-29 | E-MTAB-5632 | biostudies-arrayexpress

CUT&Tag sequencing in PDAC cells with Setd2-KO and Setd2-WT sorted from orthotopic PDAC tumor

Project description:To gain mechanistic insight into how Setd2 loss reprogramming tumor cell metabolism, we performed CUT&Tag sequencing in PDAC cells with Setd2-KO and Setd2-WT sorted from orthotopic PDAC tumor. Setd2-WT and -KO murine PDAC cells were sorted with DAPI-CD45.2-Pdpn-Epcam+ or cultured, and freshly collected as soon as possible. Hyperactive pA-Tn5 Transposase for CUT&Tag kit from Vazyme (TD901), and antibodies against H3K36me3, H3K27Ac and H3K27me3 were employed. Trueprep index kit v2 and v3 for illumina were used to establish DNA library.

2024-08-07 | GSE196241 | GEO

Transcriptomic analysis of tumor infiltrating CD8+ T cells during PDAC progression

Project description:Transcriptomic analysis of tumor infiltrating CD8+ T cells during PDAC progression

| PRJNA614931 | ENA

RNA-seq of PDAC tissues grown as patient-derived tumor xenografts

Project description:RNA-seq of PDAC tissues grown as patient-derived tumor xenografts

| PRJEB21561 | ENA

RNA-seq of pancreatic mouse tumor cell lines

Project description:KRAS-mutant pancreatic ductal adenocarcinoma (PDAC) is highly immunosuppressive and resistant to targeted therapies, immune checkpoint blockade and engineered T cells. In this study, we performed a systematic high throughput combinatorial drug screen and identified a synergistic interaction between the MEK inhibitor trametinib and the multi-kinase inhibitor nintedanib. Using bulk and single-cell RNA sequencing and immunophenotyping, we show that the combination therapy reprograms the immunosuppressive microenvironment and primes cytotoxic and memory T cells to infiltrate the tumors, thereby sensitizing mesenchymal PDAC to PD-L1 inhibition.

2021-11-29 | E-MTAB-11187 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data